Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
APG-20-OLE: Metreleptin in Partial Lipodystrophy
NCT06679270Phase 3Recruiting
- Sponsor
- Chiesi Farmaceutici S.p.A.
- Start
- Oct 2024
- Primary completion
- Mar 2028
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of metreleptin in familial partial lipodystrophy (FPLD), sponsored by Chiesi Farmaceutici S.p.A. Primary endpoint: Incidence and Frequency of Treatment-Emergent Adverse Events at 24 months. Started Oct 2024; status: recruiting.
02
Drugs
metreleptin
03
Conditions
familial partial lipodystrophy (FPLD)
Beyond the preview
Go deeper on NCT06679270.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06679270.